{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Darolutamide&page=2", "query": { "intervention": "Darolutamide", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Darolutamide&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T00:03:00.877Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05059236", "title": "A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Hormone-sensitive Prostate Cancer" ], "interventions": [ { "name": "Darolutamide (BAY1841788, Nubeqa)", "type": "DRUG" }, { "name": "ADT", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 223, "start_date": "2021-11-04", "completion_date": "2026-06-15", "has_results": true, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-09-27T00:03:00.877Z", "location_count": 31, "location_summary": "Homewood, Alabama • Tucson, Arizona • Los Angeles, California + 24 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05059236" }, { "nct_id": "NCT07142551", "title": "Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Testosterone cypionate", "type": "DRUG" }, { "name": "Luteinizing hormone-releasing hormone (LHRH) analogue", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2026-03-09", "completion_date": "2034-06-01", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-09-27T00:03:00.877Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07142551" }, { "nct_id": "NCT03551782", "title": "A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castration-Resistant Prostatic Neoplasms" ], "interventions": [ { "name": "Cetrelimab 480 mg", "type": "DRUG" }, { "name": "Apalutamide 240 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 33, "start_date": "2018-06-28", "completion_date": "2021-11-11", "has_results": false, "last_update_posted_date": "2022-02-25", "last_synced_at": "2026-09-27T00:03:00.877Z", "location_count": 11, "location_summary": "San Francisco, California • Shreveport, Louisiana • Ann Arbor, Michigan + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Bay Saint Louis", "state": "Mississippi" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03551782" }, { "nct_id": "NCT07611110", "title": "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Deutenzalutamide", "type": "DRUG" }, { "name": "Radium-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 670, "start_date": "2026-05-04", "completion_date": "2030-06-06", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-27T00:03:00.877Z", "location_count": 26, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Duarte, California + 23 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07611110" }, { "nct_id": "NCT06120491", "title": "Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-Sensitive Prostate Cancer" ], "interventions": [ { "name": "Saruparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "MALE", "summary": "18 Years to 130 Years · Male only" }, "enrollment_count": 1898, "start_date": "2023-11-21", "completion_date": "2031-04-30", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-27T00:03:00.877Z", "location_count": 71, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 63 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06120491" }, { "nct_id": "NCT07103018", "title": "A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Metastatic Castration-Resistant Prostate Cancer Patients", "Metastatic Castration-resistant Prostate Cancer, mCRPC", "mCRPC", "mCRPC (Metastatic Castration-resistant Prostate Cancer)" ], "interventions": [ { "name": "KTX-2001", "type": "DRUG" }, { "name": "KTX-2001 + Darolutamide (NUBEQA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "K36 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 144, "start_date": "2025-11-21", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-27T00:03:00.877Z", "location_count": 13, "location_summary": "San Francisco, California • Miami, Florida • Port Saint Lucie, Florida + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07103018" }, { "nct_id": "NCT07645326", "title": "RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)" ], "interventions": [ { "name": "Androgen Deprivation Therapy (ADT)", "type": "DRUG" }, { "name": "Androgen Receptor Pathway Inhibitor (ARPI)", "type": "DRUG" }, { "name": "Prostate Radiation", "type": "RADIATION" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 108, "start_date": "2026-08", "completion_date": "2032-08", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-27T00:03:00.877Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07645326" }, { "nct_id": "NCT05526248", "title": "A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biochemically Recurrent Prostate Cancer" ], "interventions": [ { "name": "Darolutamide(BAY1841788, Nubeqa)", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 28, "start_date": "2022-12-19", "completion_date": "2024-12-04", "has_results": true, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-09-27T00:03:00.877Z", "location_count": 5, "location_summary": "Sherman Oaks, California • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Sherman Oaks", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Gahanna", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05526248" }, { "nct_id": "NCT04157088", "title": "Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Cancer, Castration-Resistant" ], "interventions": [ { "name": "Darolutamide (Nubeqa, BAY1841788)", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2019-12-17", "completion_date": "2022-07-08", "has_results": true, "last_update_posted_date": "2023-08-04", "last_synced_at": "2026-09-27T00:03:00.877Z", "location_count": 7, "location_summary": "Portland, Maine • Voorhees Township, New Jersey • The Bronx, New York + 4 more", "locations": [ { "city": "Portland", "state": "Maine" }, { "city": "Voorhees Township", "state": "New Jersey" }, { "city": "The Bronx", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Bala-Cynwyd", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04157088" }, { "nct_id": "NCT06013475", "title": "An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "Darolutamide (BAY 1841788)", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1375, "start_date": "2023-08-31", "completion_date": "2024-10-28", "has_results": false, "last_update_posted_date": "2025-06-12", "last_synced_at": "2026-09-27T00:03:00.877Z", "location_count": 1, "location_summary": "Whippany, New Jersey", "locations": [ { "city": "Whippany", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06013475" } ] }